Immunome stops Covid-19 work; Hookipa drops CMV vaccine
Immunome is looking for a partner for its Covid-19 antibody cocktail known as IMM-BCP-01, according to its annual report released Thursday morning. Until then, it will stop further development of the candidate.
The Exton, PA-based biotech had tested the antibody cocktail in a Phase Ib trial with an estimated enrollment of 36 people who have mild to moderate Covid-19, according to a federal clinical trials database. The trial was run in collaboration with the US DoD and was meant to look at the safety of the drug. Immunome said there were no significant treatment-related adverse events.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters